Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.47 |
| ▸ | CA1 | P00915 | 6/20 | 0.47 |
| ▸ | CA2 | P00918 | 6/20 | 0.47 |
| ▸ | CA4 | P22748 | 6/20 | 0.47 |
| ▸ | CA9 | Q16790 | 6/20 | 0.47 |
| ▸ | CA3 | P07451 | 2/20 | 0.38 |
| ▸ | CA6 | P23280 | 2/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7548673 | 1.00 | CA12 (0.47) | CA12CA1CA2CA4CA9 | |
| SCHEMBL7527051 | 1.00 | CA12 (0.47) | CA12CA1CA2CA4CA9 | |
| SCHEMBL7548526 | 1.00 | CA12 (0.47) | CA12CA1CA2CA4CA9 | |
| SCHEMBL8259026 | 1.00 | CA12 (0.47) | CA12CA1CA2CA4CA9 | |
| SCHEMBL7551125 | 1.00 | CA12 (0.47) | CA12CA1CA2CA4CA9 | |
| SCHEMBL7541404 | 1.00 | CA12 (0.47) | CA12CA1CA2CA4CA9 | |
| SCHEMBL7549199 | 1.00 | CA12 (0.47) | CA12CA1CA2CA4CA9 | |
| Hydrochloric Acid SCHEMBL7532450 | 0.98 | CA12 (0.46) | CA12CA1CA2CA4CA9 | |
| SCHEMBL457477 | 0.98 | — | — | |
| Nitric Acid SCHEMBL2564368 | 0.91 | CA12 (0.42) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2887927-B1 | EXTENDED RELEASE COMPOSITIONS OF AN AMINO-C2-C6-ALKYL NITRATE | CARDIOLYNX AG (CH) | 2018-03-28 | — | — | EP | disclosed |
| US-20180036259-A1 | NO DONORS FOR THE TREATMENT OF IMPAIRED TISSUE PERFUSION | MIRANDAPHARMACEUTICALS AG (CH) | 2018-02-08 | — | — | US | disclosed |
| US-20180008558-A1 | EXTENDED RELEASE COMPOSITIONS OF AN AMINOALKYL NITRATE | CARDIOLYNX AG (CH) | 2018-01-11 | — | — | US | disclosed |
| US-20170100350-A1 | EXTENDED RELEASE COMPOSITIONS OF AN AMINOALKYL NITRATE | CARDIOLYNX AG (CH) | 2017-04-13 | — | — | US | disclosed |
| WO-2016135262-A1 | NO DONORS FOR THE TREATMENT OF IMPAIRED TISSUE PERFUSION | CARDIOLYNX AG (CH) | 2016-09-01 | — | — | WO | disclosed |
| WO-2016135263-A1 | NO DONORS FOR THE TREATMENT OF STRESS-INDUCED PULMONARY HAEMORRHAGE IN ANIMALS | SCHERHAG ARMIN (CH) | 2016-09-01 | — | — | WO | disclosed |
| CN-104869985-A | Extended release compositions of an aminoalkyl nitrate | CARDIOLYNX AG | 2015-08-26 | — | — | CN | disclosed |
| US-20150216992-A1 | EXTENDED RELEASE COMPOSITIONS OF AN AMINOALKYL NITRATE | CARDIOLYNX AG (CH) | 2015-08-06 | — | — | US | disclosed |
| EP-2887927-A1 | EXTENDED RELEASE COMPOSITIONS OF AN AMINOALKYL NITRATE | Cardiolynx AG (CH) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014029841-A1 | EXTENDED RELEASE COMPOSITIONS OF AN AMINOALKYL NITRATE | CARDIOLYNX AG (CH) | 2014-02-27 | — | — | WO | disclosed |
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090048219-A1 | ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2007123818-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF PROSTAGLANDINS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007016136-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2006099058-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048219-A1 | ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS3, NOS1, NOS2 | CA12 3352/4885CA1 3679/4885CA2 1214/4885 |
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NOS2, NOS3, NOS1 | CA12 3513/4885CA1 3330/4885CA2 728/4885 |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NOS3, REN, NOS1 | CA12 4070/4885CA1 3341/4885CA2 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.